 |
 |
 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
|
[Vol.35 No.1 contents] Japanese / English |
|
| ArticleTitle | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing system following the reclassification of COVID-19 to category V infectious disease -Report of a questionnaire survey in Ishikawa Prefecture- |
| Language | J |
| AuthorList | Miho Okada1), Yukie Katayama2), Akiko Niikawa3), Hatsumi Otani4), Yoshitsugu Iinuma5) |
| Affiliation |
1) Department of Clinical Laboratory, Saiseikai Kanazawa Hospital 2) Department of Clinical Laboratory, Asanogawa General Hospital 3) Department of Clinical Laboratory, Ishikawa Prefectural Hospital of Mental Health 4) Department of Clinical Laboratory, Kanazawa University Hospital 5) Department of Infectious Diseases, Kanazawa Medical University |
| Publication | J.J.C.M.: 35 (1), 27-33, 2024 |
| Received | May 28, 2024 |
| Accepted | October 7, 2024 |
| Abstract | This study was conducted to investigate the status of SARS-CoV-2 testing following the reclassification of COVID-19 to category V infectious disease. A questionnaire was sent to 71 facilities in Ishikawa Prefecture, and the results were compared with a previous study conducted during the pandemic phase. Responses were received from 53 facilities. Forty-five facilities (86.5%) were able to perform nucleic acid amplification testing on-site, an increase compared to the previous survey. The number of facilities where doctors were responsible for specimen collection decreased, while the proportion of nurses and laboratory technologists increased. Additionally, more than half (52.3%) of the facilities reported results within one hour, and these facilities had higher rates of ID NOW (Abbott Diagnostics Medical) ownership. Screening all inpatients was mainly performed for infection control and prevention at 26 facilities (55.3%), but many facilities indicated that they were discontinuing screening tests and shifting to antigen tests. Among the most common alternative uses of the equipment purchased for SARS-CoV-2 testing were tuberculosis and Clostridioides difficile (CD) toxin gene testing. It is expected that the problems that have prevented the introduction of other tests will be resolved and that the equipment will be widely used. |
| Keywords | SARS-CoV-2 |
| Copyright © 2002 The Japanese Society for Clinical Microbiology All rights reserved. |